Skip to content

Orthopaedic Treatment in Propulsive Metatarsalgia

Effectiveness of Orthopaedic Treatment in Propulsive Metatarsalgia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05713175
Enrollment
80
Registered
2023-02-06
Start date
2022-01-01
Completion date
2023-01-01
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Foot, Foot Diseases, Metatarsalgia, Orthopedic Disorder, Subluxation of Toe Joint, Toe Joint Deformity, Treatment

Keywords

Metatarsalgia, Forefoot, Foot Diseases, Treatment

Brief summary

The goal of this clinical trial is to compare the effectiveness of two conservative orthopedic treatments in propulsive metatarsalgia. The main question it aims to answer are: * To compare the effectiveness of treatments on foot pain and functionality in subjects diagnosed with propulsive metatarsalgia. * To determinate the influence of clinical and radiographical characteristics in pain improvement. Participants will wear the treatment for 3 months . Researchers will compare polypropylene and EVA insoles and Fixtoe Device® to see if a foot pain improvement is achieved.

Detailed description

Type of Study: Randomised Clinical Trial. Aim: To compare the effect of orthopedic treatment on foot pain and functionality in subjects diagnosed with propulsive metatarsalgia. Study Protocol Description: Prior to the start of the study, a calculation of the sample size will be made using the GRANMO Sample Size Calculator, version .12 April 2012, with an error of 5%, assuming a confidence level of 95% and values of ß that establish an analysis power of 80%. The study population will be randomly divided into two treatment groups, which, in turn, will be subdivided into two groups. Said randomization will be carried out using an online tool (www.randomization.com). Treatment groups are: * Group A: Treatment by custom insoles made of 4.5mm polypropylene, balanced in inversion 0-4º, MLA of the patient, 4mm-heel rise and metatarsal dome. * Group A1: Treatment from the date of diagnosis until the start of insoles use (3 weeks) using the Fix-Toe® device. * Group A2: Without orthopedic treatment from the date of diagnosis until the start of insoles use (3 weeks). * Group B: Treatment by custom insoles made of 45º shore A E.V.A with the patient's MLA, 4mm- heel rise and metatarsal dome. * Group B1: Treatment from the date of diagnosis until the start of insoles use (3 weeks) using the Fix-Toe® device. * Group B2: Without orthopedic treatment from the date of diagnosis until the start of insoles use (3 weeks). Visits protocol is as follows: * Day 1: inclusion, clinical and radiographical evaluation. Pain questionnaires fulfillment.Treatment group allocation. * Day 2 (3 weeks after Day 1): Pain questionnaires fulfillment. Starts insoles treatment. * Day 3 (6 weeks after Day 2): Pain questionnaires fulfillment (telephone). * Day 4 (6 weeks after Day 3): Pain questionnaires fulfillment. Clinical evaluation. End of study.

Interventions

DEVICEEVA plantar orthosis

Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.

DEVICEPolypropylene plantar orthosis

Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.

DEVICEFixtoe device

Fixtoe Device, simulating the metatarsophalangeal stabilization tape technique is worn for one month, prior to definitive treatment consisting of a personalized plantar orthosis.

Sponsors

Universidad Complutense de Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

The participant understands he is being part of a clinical trial but unknowns the treatment group he has been allocated.

Intervention model description

Parallel Groups Open Randomised Clinical Trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Mechanical pain in the 2nd or 3rd metatarsophalangeal joint (MTPJ) * Positive Laschman's drawer test in 2nd or 3rd MTPJ. (CITA) * Physical exploration revealing pain upon the palpation in plantar plate ( when cranial-caudal pressure was directly applied in the plantar aspect of the 2nd or 3rd MTPJ). (CITA) * Availability of dorsal-plantar and lateral wheightbearing radiography of the affected foot.

Exclusion criteria

* Subjects with at least one of the following were excluded. * Deformity of the 2nr or 3rd metatarsal head (MTH) (Freiberg's disease) * Morton's neuroma and/or neuritic symptomatlogy y referred. * Rigid claw or hammer toe (positive Kelikian test) whithin radiographic dislocation of 2nd or 3rd MTPJ. (CITA) * Dermatological lesión plantar to 2nd or 3rd MTPJ (intractable plantar keratosis (IPK), foot ulcer, plantar wart, etc.) * Neurological, methabolical, vascular or rheumatological not-controlled systemic disease with potential manifestations in foot and ankle. * Previous history of foot or ankle surgery entailing limitations in mobility and/or alterations of the metatarsal parabola. * Previous history of foot or ankle fracture * Morpho-functional alteration of the lower limbs: clinical asymmetry greater than 10 mm and presence of asymmetric genu varus or valgus. * Alterations of the cognitive state preventing to understand the objective of the study and guidelines to follow for their participation.

Design outcomes

Primary

MeasureTime frameDescription
Foot PainUp to 20 weeks.Foot Pain measured using a 11-point VAS score. 0 is the lower (better) value and 10 is the higher (worst) value.
Foot Pain and DisabilityUp to 20 weeks.Measured using the Foot Function Index (FFI-Sp) questionnaire (Spanish version). Higher values mean worse outcome and lower values mean better outcome.

Secondary

MeasureTime frameDescription
Demographic data: GenderDay 1.Women or Men
Demographic data: WheightDay 1.Expressed in kilograms.
Demographic data: HeightDay 1.Expressed in centimetres.
Demographic data: Body Mass Index (BMI)Day 1.Weight and Height will be combined to report BMI in kg/m\^2
Demographic data: Adherence to treatmentDay 2, Day 3, Day 4.Good / Bad. Measured using a own questionnaire.
Demographic data: Time with symptoms.Day 1.\>12 months / 6-12 months / \> 6 months / \> 3 months
Foot clinical evaluation data: Toes deformityDay 1.No deformity / Sagittal plane deformity / V sign
Foot clinical evaluation data: Paper pull-out testDay 1, Day 2.No resistence / Medium resistence / Resistence
Radiographical data: 2nd - 3rd metatatsophalangeal joint radiolucency.Day 1.Yes / No
Foot clinical evaluation data: 1st metatarsophalangeal joint range of movementDay 1, Day 4Expressed in degrees.
Foot clinical evaluation data: Medial column of the foot stiffnessDay 1.Low / Moderate/ High
Foot clinical evaluation data: Functional Hallux LimitusDay 1.Yes / No. According to Functional Hallux Limitus test.
Foot clinical evaluation data: First ray mobilityDay 1.Dorsal \> Plantar / Similar / Dorsal \< Plantar
Foot clinical evaluation data: Lunge testDay 1.Positive / Negative
Foot clinical evaluation data: Arch indexDay 1, Day 4.Expressed in degrees.
Foot clinical evaluation data: Navicular Drop TestDay 1, Day 4.Expressed in centimetres.
Radiographical data: 1st cuneiform - 2nd metatarsal gapDay 1.Expressed in centimetres.
Foot clinical evaluation data: Subtalar joint axis orientationDay 1.Medial / Neutral / Lateral
Radiographical data: HAV angleDay 1.Expressed in degrees.
Radiographical data: 1st metatarsophalangeal joint osteoarthritisDay 1.0/ 1/ 2/ 3/ 4
Metatarsal formulaDay 1.According to the length of the metatarsal bones.
Radiographical data: 2nd metatarsophalangeal joint angleDay 1.Expressed in degrees.
Radiographical data: 3rd metatarsophalangeal joint angleDay 1.Expressed in degrees.
Radiographical data: M1-M2 intermetatarsal angleDay 1.Expressed in degrees.
Radiographical data: 2nd- 3rd metatarsophalangeal joint impingementDay 1.Yes / No
Radiographical data: Metatarsus primus elevatusDay 1.Yes / No
Radiographical data: talar coverage angleDay 1.Expressed in degrees.
Radiographical data: 1st cuneiform - 5th metatarsal distanceDay 1.Expressed in centimetres.
Radiographical data: Meary's lineDay 1.Dorsal / Plantar
Foot orthosis data: Metatarsal dome location in relation to central metatarsal headsDay 4.Similar / Distal / Proximal
Foot orthosis data: Metatarsal dome location in relation to 1st metatarsal headDay 4.Similar / Distal / Proximal
Foot orthosis data: StabilityDay 4.Yes / No
Foot orthosis data: Orthotic deformity testDay 4.Yes / No
Foot clinical evaluation data: Calcaneus relaxed standing position.Day 1, Day 4.Expressed in degrees.
Demographic data: Age.Day 1.Expressed in years

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026